Skip to main content
. 2012 Mar;50(3):823–830. doi: 10.1128/JCM.00750-11

Table 3.

Factors at baseline associated with day 45 evaluation for all patients

Variablea Data [no., no. (%), or median (range)] for indicated patient(s)
Pb
Responder (n = 3) Nonresponder (n = 2) Undetermined (n = 2)
Age (yr) 52.1 (15.6–77.8) 45.3 (9.8–71.9) 31.5 and 63.9 0.53
Patient risk category 0.29
    Allogeneic HSCT 10 (33) 13 (52) 0 (0)
    AL 15 (50) 7 (28) 1 (50)
    Others 5 (17) 5 (20) 1 (50)
EORTC-defined IA 0.060
    Proven 2 (7) 2 (8) 0 (0)
    Probable 20 (67) 22 (88) 2 (100)
    Possible 8 (27) 1 (4) 0 (0)
Leukocyte count of <100/mm3 at diagnosis 15 (50) 12 (48) 0 (0) 1.00
Receiving corticosteroids 11 (37) 18 (72) 2 (100) 0.014
Cumulative dose of prednisone the week before diagnosis (mg/kg of body wt) 0.0 (0.0–11.0) 7.0 (0.0–28.0) 7.0 and 31.0 0.002
Received immunosuppressive therapy for <1 month 8 (27) 12 (48) 0 (0) 0.16
Received antimold therapy for <15 days 15 (50) 19 (76) 0 (0) 0.057
Concomitant pulmonary infection 8 (27) 8 (32) 0 (0) 0.77
Serum GM antigen value 0.4 (0.0–9.3) 1.1 (0.1–11.0) 0.2 and 4.8 0.039
    Patient(s) with value of ≥0.5 14 (47) 15 (60) 1 (50) 0.42
BAL fluid GM antigen value 3.4 (0.1–9.8) 0.4 (0.0–7.0) 0.096
    Patients with value of ≥0.5 10 (71) 8 (53) 0.45
Anti-Aspergillus antibody value 3.3 (0.1–181.0) 3.2 (1.0–108.0) 0.2 and 8.1 0.79
    Patients with value of ≥12 4 (14) 6 (24) 0 (0) 0.49
Positive mycological examination of respiratory samples 13 (57) 14 (67) 1 (100) 0.55
Positive PCR Aspergillus fumigatus 2 (9) 3 (20) 0 (0) 0.36
Positive PCR Aspergillus spp 13 (57) 4 (29) 1 (100) 0.17
First-line treatment with voriconazole 22 (73) 20 (80) 1 (50) 0.75
Halo sign 19 (63) 14 (56) 0 (0) 0.59
a

HSCT, hematopoietic stem cell transplantation; GVHD, graft versus host disease; AL, acute leukemia; CS, corticosteroids; GM, galactomannan.

b

Fisher's exact test or Wilcoxon rank-sum test for responders versus nonresponders.